nodes	percent_of_prediction	percent_of_DWPC	metapath
Latanoprost—PTGFR—prostate gland—urinary bladder cancer	0.0364	0.19	CbGeAlD
Latanoprost—Dinoprost Tromethamine—HPGDS—urinary bladder cancer	0.0304	0.741	CrCbGaD
Latanoprost—PTGFR—smooth muscle tissue—urinary bladder cancer	0.0257	0.134	CbGeAlD
Latanoprost—Scab—Fluorouracil—urinary bladder cancer	0.025	0.0326	CcSEcCtD
Latanoprost—PTGFR—urethra—urinary bladder cancer	0.0243	0.127	CbGeAlD
Latanoprost—Stinging—Mitomycin—urinary bladder cancer	0.0236	0.0308	CcSEcCtD
Latanoprost—SLCO2B1—prostate gland—urinary bladder cancer	0.0201	0.105	CbGeAlD
Latanoprost—PTGFR—female reproductive system—urinary bladder cancer	0.0199	0.104	CbGeAlD
Latanoprost—Urinary tract infection—Valrubicin—urinary bladder cancer	0.0151	0.0197	CcSEcCtD
Latanoprost—Embolism—Thiotepa—urinary bladder cancer	0.015	0.0195	CcSEcCtD
Latanoprost—SLCO2B1—renal system—urinary bladder cancer	0.0137	0.0714	CbGeAlD
Latanoprost—SLC22A1—renal system—urinary bladder cancer	0.0131	0.0682	CbGeAlD
Latanoprost—Blepharitis—Fluorouracil—urinary bladder cancer	0.0129	0.0169	CcSEcCtD
Latanoprost—Back pain—Valrubicin—urinary bladder cancer	0.0117	0.0153	CcSEcCtD
Latanoprost—PTGFR—lymph node—urinary bladder cancer	0.0116	0.0606	CbGeAlD
Latanoprost—SLCO2B1—female reproductive system—urinary bladder cancer	0.0109	0.0572	CbGeAlD
Latanoprost—Dermatitis atopic—Gemcitabine—urinary bladder cancer	0.0109	0.0142	CcSEcCtD
Latanoprost—Tafluprost—PTGS2—urinary bladder cancer	0.0106	0.259	CrCbGaD
Latanoprost—Chest pain—Valrubicin—urinary bladder cancer	0.0103	0.0135	CcSEcCtD
Latanoprost—Discomfort—Valrubicin—urinary bladder cancer	0.0102	0.0133	CcSEcCtD
Latanoprost—Stinging—Fluorouracil—urinary bladder cancer	0.00982	0.0128	CcSEcCtD
Latanoprost—SLC22A1—vagina—urinary bladder cancer	0.00946	0.0494	CbGeAlD
Latanoprost—Eye irritation—Fluorouracil—urinary bladder cancer	0.00932	0.0121	CcSEcCtD
Latanoprost—Photophobia—Thiotepa—urinary bladder cancer	0.00903	0.0118	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00903	0.0118	CcSEcCtD
Latanoprost—Lacrimation increased—Fluorouracil—urinary bladder cancer	0.00864	0.0113	CcSEcCtD
Latanoprost—Erythema—Mitomycin—urinary bladder cancer	0.00836	0.0109	CcSEcCtD
Latanoprost—Inflammation—Fluorouracil—urinary bladder cancer	0.0082	0.0107	CcSEcCtD
Latanoprost—Vision blurred—Mitomycin—urinary bladder cancer	0.00788	0.0103	CcSEcCtD
Latanoprost—Pain—Carboplatin—urinary bladder cancer	0.00785	0.0102	CcSEcCtD
Latanoprost—Photophobia—Fluorouracil—urinary bladder cancer	0.00747	0.00974	CcSEcCtD
Latanoprost—Inflammation—Etoposide—urinary bladder cancer	0.00712	0.00928	CcSEcCtD
Latanoprost—Discomfort—Mitomycin—urinary bladder cancer	0.00703	0.00917	CcSEcCtD
Latanoprost—Pruritus—Valrubicin—urinary bladder cancer	0.00701	0.00913	CcSEcCtD
Latanoprost—Oedema—Mitomycin—urinary bladder cancer	0.00683	0.00889	CcSEcCtD
Latanoprost—Hepatic function abnormal—Gemcitabine—urinary bladder cancer	0.00672	0.00876	CcSEcCtD
Latanoprost—Dizziness—Valrubicin—urinary bladder cancer	0.00655	0.00854	CcSEcCtD
Latanoprost—Embolism—Methotrexate—urinary bladder cancer	0.00645	0.0084	CcSEcCtD
Latanoprost—SLCO2B1—lymph node—urinary bladder cancer	0.0064	0.0334	CbGeAlD
Latanoprost—Rash—Valrubicin—urinary bladder cancer	0.00625	0.00814	CcSEcCtD
Latanoprost—Dermatitis—Valrubicin—urinary bladder cancer	0.00624	0.00813	CcSEcCtD
Latanoprost—Headache—Valrubicin—urinary bladder cancer	0.00621	0.00809	CcSEcCtD
Latanoprost—Dyspnoea—Mitomycin—urinary bladder cancer	0.00609	0.00793	CcSEcCtD
Latanoprost—Embolism—Epirubicin—urinary bladder cancer	0.00604	0.00786	CcSEcCtD
Latanoprost—Keratitis—Epirubicin—urinary bladder cancer	0.00597	0.00778	CcSEcCtD
Latanoprost—Pain—Mitomycin—urinary bladder cancer	0.00584	0.00761	CcSEcCtD
Latanoprost—Embolism—Doxorubicin—urinary bladder cancer	0.00558	0.00728	CcSEcCtD
Latanoprost—Keratitis—Doxorubicin—urinary bladder cancer	0.00553	0.0072	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.00529	0.00689	CcSEcCtD
Latanoprost—Dermatitis atopic—Epirubicin—urinary bladder cancer	0.00523	0.00682	CcSEcCtD
Latanoprost—Conjunctivitis—Thiotepa—urinary bladder cancer	0.00523	0.00682	CcSEcCtD
Latanoprost—Angina pectoris—Fluorouracil—urinary bladder cancer	0.00486	0.00634	CcSEcCtD
Latanoprost—Dermatitis atopic—Doxorubicin—urinary bladder cancer	0.00484	0.00631	CcSEcCtD
Latanoprost—Stinging—Epirubicin—urinary bladder cancer	0.00478	0.00623	CcSEcCtD
Latanoprost—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.00475	0.00619	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00464	0.00605	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.00452	0.00589	CcSEcCtD
Latanoprost—Dizziness—Mitomycin—urinary bladder cancer	0.00451	0.00588	CcSEcCtD
Latanoprost—Stinging—Doxorubicin—urinary bladder cancer	0.00442	0.00577	CcSEcCtD
Latanoprost—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00435	0.00567	CcSEcCtD
Latanoprost—Conjunctivitis—Fluorouracil—urinary bladder cancer	0.00433	0.00564	CcSEcCtD
Latanoprost—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00433	0.00564	CcSEcCtD
Latanoprost—Rash—Mitomycin—urinary bladder cancer	0.0043	0.00561	CcSEcCtD
Latanoprost—Dermatitis—Mitomycin—urinary bladder cancer	0.0043	0.0056	CcSEcCtD
Latanoprost—Headache—Mitomycin—urinary bladder cancer	0.00428	0.00557	CcSEcCtD
Latanoprost—Inflammation—Methotrexate—urinary bladder cancer	0.00427	0.00556	CcSEcCtD
Latanoprost—Erythema—Thiotepa—urinary bladder cancer	0.00421	0.00548	CcSEcCtD
Latanoprost—Lacrimation increased—Epirubicin—urinary bladder cancer	0.0042	0.00548	CcSEcCtD
Latanoprost—Conjunctivitis—Cisplatin—urinary bladder cancer	0.0041	0.00534	CcSEcCtD
Latanoprost—Back pain—Thiotepa—urinary bladder cancer	0.00407	0.0053	CcSEcCtD
Latanoprost—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00399	0.0052	CcSEcCtD
Latanoprost—Inflammation—Epirubicin—urinary bladder cancer	0.00399	0.0052	CcSEcCtD
Latanoprost—Vision blurred—Thiotepa—urinary bladder cancer	0.00396	0.00516	CcSEcCtD
Latanoprost—Lacrimation increased—Doxorubicin—urinary bladder cancer	0.00389	0.00507	CcSEcCtD
Latanoprost—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00372	0.00485	CcSEcCtD
Latanoprost—Inflammation—Doxorubicin—urinary bladder cancer	0.0037	0.00482	CcSEcCtD
Latanoprost—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00366	0.00477	CcSEcCtD
Latanoprost—Arthralgia—Thiotepa—urinary bladder cancer	0.00358	0.00467	CcSEcCtD
Latanoprost—Dry eye—Epirubicin—urinary bladder cancer	0.00358	0.00466	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00356	0.00463	CcSEcCtD
Latanoprost—Erythema—Gemcitabine—urinary bladder cancer	0.00354	0.00461	CcSEcCtD
Latanoprost—Erythema—Fluorouracil—urinary bladder cancer	0.00348	0.00453	CcSEcCtD
Latanoprost—Back pain—Gemcitabine—urinary bladder cancer	0.00342	0.00446	CcSEcCtD
Latanoprost—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00341	0.00445	CcSEcCtD
Latanoprost—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00337	0.00439	CcSEcCtD
Latanoprost—Skin disorder—Thiotepa—urinary bladder cancer	0.00333	0.00434	CcSEcCtD
Latanoprost—Dry eye—Doxorubicin—urinary bladder cancer	0.00331	0.00431	CcSEcCtD
Latanoprost—Erythema—Cisplatin—urinary bladder cancer	0.0033	0.0043	CcSEcCtD
Latanoprost—Vision blurred—Fluorouracil—urinary bladder cancer	0.00328	0.00427	CcSEcCtD
Latanoprost—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00322	0.00419	CcSEcCtD
Latanoprost—Eczema—Epirubicin—urinary bladder cancer	0.00313	0.00408	CcSEcCtD
Latanoprost—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00313	0.00408	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00313	0.00407	CcSEcCtD
Latanoprost—Eye pain—Epirubicin—urinary bladder cancer	0.00312	0.00406	CcSEcCtD
Latanoprost—Vision blurred—Cisplatin—urinary bladder cancer	0.00311	0.00405	CcSEcCtD
Latanoprost—Chest pain—Gemcitabine—urinary bladder cancer	0.00301	0.00392	CcSEcCtD
Latanoprost—Arthralgia—Gemcitabine—urinary bladder cancer	0.00301	0.00392	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00299	0.0039	CcSEcCtD
Latanoprost—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00298	0.00388	CcSEcCtD
Latanoprost—Discomfort—Gemcitabine—urinary bladder cancer	0.00298	0.00388	CcSEcCtD
Latanoprost—Chest pain—Fluorouracil—urinary bladder cancer	0.00296	0.00386	CcSEcCtD
Latanoprost—Pain—Thiotepa—urinary bladder cancer	0.00294	0.00382	CcSEcCtD
Latanoprost—Discomfort—Fluorouracil—urinary bladder cancer	0.00293	0.00381	CcSEcCtD
Latanoprost—Back pain—Etoposide—urinary bladder cancer	0.00292	0.00381	CcSEcCtD
Latanoprost—Eczema—Doxorubicin—urinary bladder cancer	0.0029	0.00377	CcSEcCtD
Latanoprost—Oedema—Gemcitabine—urinary bladder cancer	0.00289	0.00376	CcSEcCtD
Latanoprost—Eye pain—Doxorubicin—urinary bladder cancer	0.00288	0.00376	CcSEcCtD
Latanoprost—Oedema—Fluorouracil—urinary bladder cancer	0.00284	0.0037	CcSEcCtD
Latanoprost—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00283	0.00369	CcSEcCtD
Latanoprost—Diplopia—Epirubicin—urinary bladder cancer	0.00281	0.00366	CcSEcCtD
Latanoprost—Skin disorder—Gemcitabine—urinary bladder cancer	0.0028	0.00365	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00279	0.00363	CcSEcCtD
Latanoprost—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00278	0.00363	CcSEcCtD
Latanoprost—Discomfort—Cisplatin—urinary bladder cancer	0.00277	0.00361	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00271	0.00353	CcSEcCtD
Latanoprost—Oedema—Cisplatin—urinary bladder cancer	0.00269	0.00351	CcSEcCtD
Latanoprost—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00264	0.00344	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00263	0.00343	CcSEcCtD
Latanoprost—Skin disorder—Cisplatin—urinary bladder cancer	0.00261	0.00341	CcSEcCtD
Latanoprost—Diplopia—Doxorubicin—urinary bladder cancer	0.0026	0.00339	CcSEcCtD
Latanoprost—Asthma—Methotrexate—urinary bladder cancer	0.0026	0.00338	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00259	0.00337	CcSEcCtD
Latanoprost—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00257	0.00335	CcSEcCtD
Latanoprost—Chest pain—Etoposide—urinary bladder cancer	0.00257	0.00335	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00255	0.00333	CcSEcCtD
Latanoprost—Discomfort—Etoposide—urinary bladder cancer	0.00254	0.00331	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00253	0.0033	CcSEcCtD
Latanoprost—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00253	0.0033	CcSEcCtD
Latanoprost—Pain—Gemcitabine—urinary bladder cancer	0.00247	0.00322	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00245	0.0032	CcSEcCtD
Latanoprost—Asthma—Epirubicin—urinary bladder cancer	0.00243	0.00317	CcSEcCtD
Latanoprost—Pruritus—Thiotepa—urinary bladder cancer	0.00243	0.00316	CcSEcCtD
Latanoprost—Pain—Fluorouracil—urinary bladder cancer	0.00243	0.00316	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00241	0.00315	CcSEcCtD
Latanoprost—Dyspnoea—Cisplatin—urinary bladder cancer	0.0024	0.00313	CcSEcCtD
Latanoprost—Skin disorder—Etoposide—urinary bladder cancer	0.0024	0.00312	CcSEcCtD
Latanoprost—Angina pectoris—Epirubicin—urinary bladder cancer	0.00237	0.00308	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00234	0.00305	CcSEcCtD
Latanoprost—Bronchitis—Epirubicin—urinary bladder cancer	0.00234	0.00305	CcSEcCtD
Latanoprost—Pain—Cisplatin—urinary bladder cancer	0.0023	0.003	CcSEcCtD
Latanoprost—Dizziness—Thiotepa—urinary bladder cancer	0.00227	0.00296	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00226	0.00294	CcSEcCtD
Latanoprost—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00225	0.00293	CcSEcCtD
Latanoprost—Asthma—Doxorubicin—urinary bladder cancer	0.00225	0.00293	CcSEcCtD
Latanoprost—Dyspnoea—Etoposide—urinary bladder cancer	0.0022	0.00286	CcSEcCtD
Latanoprost—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00219	0.00285	CcSEcCtD
Latanoprost—Rash—Thiotepa—urinary bladder cancer	0.00216	0.00282	CcSEcCtD
Latanoprost—Bronchitis—Doxorubicin—urinary bladder cancer	0.00216	0.00282	CcSEcCtD
Latanoprost—Dermatitis—Thiotepa—urinary bladder cancer	0.00216	0.00282	CcSEcCtD
Latanoprost—Headache—Thiotepa—urinary bladder cancer	0.00215	0.0028	CcSEcCtD
Latanoprost—Pain—Etoposide—urinary bladder cancer	0.00211	0.00275	CcSEcCtD
Latanoprost—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00211	0.00274	CcSEcCtD
Latanoprost—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00211	0.00274	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00209	0.00272	CcSEcCtD
Latanoprost—Pruritus—Gemcitabine—urinary bladder cancer	0.00204	0.00266	CcSEcCtD
Latanoprost—Pruritus—Fluorouracil—urinary bladder cancer	0.00201	0.00262	CcSEcCtD
Latanoprost—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00195	0.00254	CcSEcCtD
Latanoprost—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00195	0.00254	CcSEcCtD
Latanoprost—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00191	0.00249	CcSEcCtD
Latanoprost—Dizziness—Fluorouracil—urinary bladder cancer	0.00188	0.00245	CcSEcCtD
Latanoprost—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00187	0.00244	CcSEcCtD
Latanoprost—Rash—Gemcitabine—urinary bladder cancer	0.00182	0.00237	CcSEcCtD
Latanoprost—Dermatitis—Gemcitabine—urinary bladder cancer	0.00182	0.00237	CcSEcCtD
Latanoprost—Erythema—Methotrexate—urinary bladder cancer	0.00181	0.00236	CcSEcCtD
Latanoprost—Headache—Gemcitabine—urinary bladder cancer	0.00181	0.00236	CcSEcCtD
Latanoprost—Rash—Fluorouracil—urinary bladder cancer	0.00179	0.00233	CcSEcCtD
Latanoprost—Dermatitis—Fluorouracil—urinary bladder cancer	0.00179	0.00233	CcSEcCtD
Latanoprost—Headache—Fluorouracil—urinary bladder cancer	0.00178	0.00232	CcSEcCtD
Latanoprost—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00177	0.0023	CcSEcCtD
Latanoprost—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00175	0.00228	CcSEcCtD
Latanoprost—Back pain—Methotrexate—urinary bladder cancer	0.00175	0.00228	CcSEcCtD
Latanoprost—Pruritus—Etoposide—urinary bladder cancer	0.00174	0.00227	CcSEcCtD
Latanoprost—Vision blurred—Methotrexate—urinary bladder cancer	0.00171	0.00222	CcSEcCtD
Latanoprost—Rash—Cisplatin—urinary bladder cancer	0.0017	0.00221	CcSEcCtD
Latanoprost—Dermatitis—Cisplatin—urinary bladder cancer	0.0017	0.00221	CcSEcCtD
Latanoprost—Erythema—Epirubicin—urinary bladder cancer	0.00169	0.00221	CcSEcCtD
Latanoprost—Back pain—Epirubicin—urinary bladder cancer	0.00164	0.00213	CcSEcCtD
Latanoprost—Dizziness—Etoposide—urinary bladder cancer	0.00163	0.00212	CcSEcCtD
Latanoprost—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00162	0.00211	CcSEcCtD
Latanoprost—Vision blurred—Epirubicin—urinary bladder cancer	0.0016	0.00208	CcSEcCtD
Latanoprost—Erythema—Doxorubicin—urinary bladder cancer	0.00157	0.00204	CcSEcCtD
Latanoprost—Rash—Etoposide—urinary bladder cancer	0.00155	0.00203	CcSEcCtD
Latanoprost—Dermatitis—Etoposide—urinary bladder cancer	0.00155	0.00202	CcSEcCtD
Latanoprost—Headache—Etoposide—urinary bladder cancer	0.00154	0.00201	CcSEcCtD
Latanoprost—Chest pain—Methotrexate—urinary bladder cancer	0.00154	0.00201	CcSEcCtD
Latanoprost—Arthralgia—Methotrexate—urinary bladder cancer	0.00154	0.00201	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00153	0.00199	CcSEcCtD
Latanoprost—Discomfort—Methotrexate—urinary bladder cancer	0.00152	0.00198	CcSEcCtD
Latanoprost—Back pain—Doxorubicin—urinary bladder cancer	0.00152	0.00197	CcSEcCtD
Latanoprost—Vision blurred—Doxorubicin—urinary bladder cancer	0.00148	0.00192	CcSEcCtD
Latanoprost—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00145	0.00189	CcSEcCtD
Latanoprost—Arthralgia—Epirubicin—urinary bladder cancer	0.00144	0.00188	CcSEcCtD
Latanoprost—Chest pain—Epirubicin—urinary bladder cancer	0.00144	0.00188	CcSEcCtD
Latanoprost—Skin disorder—Methotrexate—urinary bladder cancer	0.00143	0.00187	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00143	0.00187	CcSEcCtD
Latanoprost—Discomfort—Epirubicin—urinary bladder cancer	0.00142	0.00186	CcSEcCtD
Latanoprost—Oedema—Epirubicin—urinary bladder cancer	0.00138	0.0018	CcSEcCtD
Latanoprost—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00136	0.00177	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00135	0.00175	CcSEcCtD
Latanoprost—Skin disorder—Epirubicin—urinary bladder cancer	0.00134	0.00175	CcSEcCtD
Latanoprost—Arthralgia—Doxorubicin—urinary bladder cancer	0.00133	0.00174	CcSEcCtD
Latanoprost—Chest pain—Doxorubicin—urinary bladder cancer	0.00133	0.00174	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00132	0.00173	CcSEcCtD
Latanoprost—Discomfort—Doxorubicin—urinary bladder cancer	0.00132	0.00172	CcSEcCtD
Latanoprost—Dyspnoea—Methotrexate—urinary bladder cancer	0.00132	0.00172	CcSEcCtD
Latanoprost—Oedema—Doxorubicin—urinary bladder cancer	0.00128	0.00167	CcSEcCtD
Latanoprost—Pain—Methotrexate—urinary bladder cancer	0.00126	0.00165	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00126	0.00164	CcSEcCtD
Latanoprost—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00125	0.00163	CcSEcCtD
Latanoprost—Skin disorder—Doxorubicin—urinary bladder cancer	0.00124	0.00162	CcSEcCtD
Latanoprost—Dyspnoea—Epirubicin—urinary bladder cancer	0.00123	0.00161	CcSEcCtD
Latanoprost—Pain—Epirubicin—urinary bladder cancer	0.00118	0.00154	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00117	0.00152	CcSEcCtD
Latanoprost—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00114	0.00149	CcSEcCtD
Latanoprost—Pain—Doxorubicin—urinary bladder cancer	0.00109	0.00142	CcSEcCtD
Latanoprost—Pruritus—Methotrexate—urinary bladder cancer	0.00104	0.00136	CcSEcCtD
Latanoprost—Pruritus—Epirubicin—urinary bladder cancer	0.000978	0.00127	CcSEcCtD
Latanoprost—Dizziness—Methotrexate—urinary bladder cancer	0.000977	0.00127	CcSEcCtD
Latanoprost—Rash—Methotrexate—urinary bladder cancer	0.000931	0.00121	CcSEcCtD
Latanoprost—Dermatitis—Methotrexate—urinary bladder cancer	0.00093	0.00121	CcSEcCtD
Latanoprost—Headache—Methotrexate—urinary bladder cancer	0.000925	0.00121	CcSEcCtD
Latanoprost—Dizziness—Epirubicin—urinary bladder cancer	0.000914	0.00119	CcSEcCtD
Latanoprost—Pruritus—Doxorubicin—urinary bladder cancer	0.000905	0.00118	CcSEcCtD
Latanoprost—Rash—Epirubicin—urinary bladder cancer	0.000871	0.00114	CcSEcCtD
Latanoprost—Dermatitis—Epirubicin—urinary bladder cancer	0.000871	0.00113	CcSEcCtD
Latanoprost—Headache—Epirubicin—urinary bladder cancer	0.000866	0.00113	CcSEcCtD
Latanoprost—Dizziness—Doxorubicin—urinary bladder cancer	0.000846	0.0011	CcSEcCtD
Latanoprost—Rash—Doxorubicin—urinary bladder cancer	0.000806	0.00105	CcSEcCtD
Latanoprost—Dermatitis—Doxorubicin—urinary bladder cancer	0.000806	0.00105	CcSEcCtD
Latanoprost—Headache—Doxorubicin—urinary bladder cancer	0.000801	0.00104	CcSEcCtD
